Skip to main content
Kisqali patient portrayal.

More life for living

KISQALI—the only CDK4/6 inhibitor to achieve statistically significant overall survival in first line in combination with an AI

MONALEESA-2: KISQALI + AI in 1L postmenopausal patients

References: 1. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp. 2. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663 3. Data on file. MONALEESA-2 final overall survival analysis. Novartis Pharmaceuticals Corp; 2021. 4. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738-1748;(protocol). doi:10.1056/NEJMoa1609709 5. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738-1748. doi:10.1056/NEJMoa1609709